The Conversation (0)
Mustang Bio announced the expansion of its pipeline of CAR T therapies into CD20-directed immunotherapies.
Mustang Bio (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) company, announced the expansion of its pipeline of CAR T therapies into CD20-directed immunotherapies.
As quoted in the press release:
Mustang has entered into an exclusive, worldwide licensing agreement with Fred Hutchinson Cancer Research Center (“Fred Hutch”) for the use of a CAR T therapy related to autologous T cells engineered to express a CD20-specific chimeric antigen receptor (“CD20 Technology”). The CAR T was developed in the laboratory of Oliver Press, M.D., Ph.D., and Brian Till, M.D., in Fred Hutch’s Clinical Research Division.
As part of the transaction, Mustang entered into an investigator-initiated clinical trial agreement to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Click here to read the full press release.
Source: globenewswire.com